MA
DNLI icon

MONECO Advisors’s Denali Therapeutics DNLI Stock Holding History

MONECO Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$213K Buy
+8,278
New +$170K 0.01% 565
2025
Q4 		– Sell
-12,478
Closed -$181K – 513
2025
Q3 		$181K Buy
12,478
+2,000
+19% +$28.7K 0.02% 489
2025
Q2 		$147K Sell
10,478
-122
-1% -$1.72K 0.01% 462
2025
Q1 		$144K Hold
10,600
– – 0.01% 447
2024
Q4 		$216K Buy
10,600
+1,500
+16% +$38.4K 0.02% 439
2024
Q3 		$265K Buy
9,100
+400
+5% +$9.91K 0.03% 370
2024
Q2 		$202K Buy
+8,700
New +$167K 0.03% 410

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MONECO Advisors's DNLI Position: Q2 2026 in Review

MONECO Advisors opened a new position in Denali Therapeutics (DNLI) in Q2 2026: 8,278 shares worth $213K. The stake represents 0.01% of the portfolio and ranks #565 among its holdings. This is a return to the name: MONECO Advisors previously reported a position in DNLI as recently as Q3 2025.

MONECO Advisors first reported a position in DNLI in Q2 2024 and has held it in 7 quarters since. The position peaked at $265K in Q3 2024. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • MONECO Advisors held 8,278 shares of Denali Therapeutics worth $213K as of Q2 2026.
  • Denali Therapeutics was a new MONECO Advisors position in Q2 2026.
  • Denali Therapeutics made up 0.01% of MONECO Advisors's portfolio in Q2 2026, its #565 holding.
  • MONECO Advisors first reported a position in Denali Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • MONECO Advisors's Denali Therapeutics position peaked at $265K in Q3 2024.
  • 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on MONECO Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.